Oxygen Biotherapeutics Announces Fiscal Year 2014 Financial Results
Wall Street Journal
… year, including proceeds from the March 2014 $59.8 million public offering of Common Stock; proceeds from the July 2013 $5.4 million public offering of Series C Preferred Stock and Warrants, and the exercise of certain outstanding warrants of $7.0 …

and more